Carlo Toniatti

IRBM Science Park — Italy

Biochemistry, Genetics and Molecular Biology · Life Sciences

49h-index10.2kcitations211works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CRISPR and Genetic Engineering(37), Virus-based gene therapy research(27), Cancer, Hypoxia, and Metabolism(26), DNA Repair Mechanisms(23), PARP inhibition in cancer therapy(23)

Publications211 total

Cyclic Peptide Inhibitors of the MLH1-MSH3 Interaction as a Potential Therapeutic Strategy for Huntington's Disease
2026Open Access
An allosteric inhibitor of the Zika virus NS2B-NS3 protease with oral efficacy in mouse models
Nature Communications·2026Open Access
Novel azabicyclic series of potent SHP2 allosteric inhibitors
Bioorganic & Medicinal Chemistry Letters·2025
Abstract 4773: AM E3-SG3249, a first-in-class α-CRLF2 antibody-drug conjugate for the treatment of CRLF2-rearranged Ph-like B-ALL
Cancer Research·2025
Abstract 5614: Advancing treatment for brain tumors and metastases with brain permeable SHP2 inhibitor I-1000233
Cancer Research·2025
Abstract 1975: Discovery of I-1000233, a potent, selective and brain permeable SHP2 allosteric inhibitor
Cancer Research·2024
Abstract 2610: Discovery of AM E3: A novel α-TLSPR monoclonal antibody for the ADC treatment of CRLF2-rearranged Ph-like B-ALL
Cancer Research·2024
Direct-to-biology platform: From synthesis to biological evaluation of SHP2 allosteric inhibitors
Bioorganic & Medicinal Chemistry Letters·2024· 5 citedOpen Access
Direct-to-Biology Platform: From Synthesis to Biological Evaluation of Shp2 Allosteric Inhibitors
SSRN Electronic Journal·2024Open Access
Discovery of a Novel Series of Potent SHP2 Allosteric Inhibitors
ACS Medicinal Chemistry Letters·2023· 11 citedOpen Access
Supplementary Figure 9 from Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
2023Open Access
Supplementary Figure 3 from Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
2023Open Access
Supplementary Figures S1 - S11 from Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i>-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
2023Open Access
Supplementary Methods, Table S2 from Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i>-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
2023Open Access
Supplementary Figure 7 from Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
2023Open Access
Supplementary Figure 1 from Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
2023Open Access
Supplementary Figure Legend from Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy
2023Open Access
Supplementary Figure 8 from Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
2023Open Access
Supplementary Figure 4 from Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
2023Open Access
Data from Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i>-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
2023Open Access
page 1 of 11Next →

Frequent Co-authors

Gennaro Ciliberto(20), Philip Jones(10), Giulio Draetta(9), Timothy P. Heffernan(9), Stefania Lamartina(8), Anna Salvati(6), Alessia Petrocchi(5), Giuseppe Roscilli(5), Armin Lahm(5), Elisabetta Sporeno(5), Valeria Poli(4), Jennifer Bardenhagen(4), Ningping Feng(4), Mary Geck(4), Virginia Giuliani(4), Yongying Jiang(4), Ronald A. DePinho(4), Joseph R. Marszalek(4), Xi Shi(4), Elisabetta Leo(4)